ArticleOsteoarthritis and cartilage open2025
Inter-assay variability in the measurement of urinary C-terminal cross-linked telopeptide of type II collagen following anterior cruciate ligament reconstruction.
Article in Osteoarthritis and cartilage open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare urinary C-terminal cross-linked telopeptide of type II collagen (u-CTX-II) concentrations and trends as measured by two different commercially available enzyme-linked immunosorbent assays (ELISA) in a cohort of patients in the first year following anterior cruciate ligament (ACL) reconstruction. Design: 22 ACL-injured patients undergoing reconstructive surgery (mean age 25.2 (SD 8.0) years; 12 (54.5 %) male) had urine samples taken on the day of surgery (baseline) and at 6 and 12 months post-operatively. Concentrations of u-CTX-II were measured using the CloudClone® and the CartiLaps® ELISA. u-CTX-II concentrations were normalized to urinary creatinine (Cr). Results: The u-CTX-II concentrations were significantly different between the 2 assays at each timepoint (p ≤ 0.01). When measured using the CloudClone® Assay, mean (standard error) u-CTX-II concentrations were 26.5 (2.5) ng/mmol Cr, 29.4 (3.8) ng/mmol Cr and 40.6 (6.9) ng/mmol Cr at the baseline, 6-month and 12-month timepoints respectively. When measured using the CartiLaps® Assay, at the same respective timepoints, u-CTX-II concentrations were 981.2 (256.5) ng/mmol Cr, 867.0 (234.3) ng/mmol Cr and 764.3 (220.3) ng/mmol Cr. Concentrations of u-CTX-II using the CloudClone® Assay increased with time (p = 0.04). Concentrations of u-CTX-II using the CartiLaps® Assay decreased over time (p = 0.2). Conclusion: Using two commercially available assays, u-CTX-II differed significantly in terms of both concentration and trends in the first year following ACL reconstruction. The specific assay used is critical to consider when interpreting results and has implications for pooling data and meta-analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.